Treatment with ureteral stenting in patients with bladder cancer, either to protect the ureteral orifice and prevent obstruction or to decompress established upper urinary tract (UUT) obstruction, appears to increase the risk of developing metachronous upper tract urothelial carcinoma (UTUC) compared with no stenting, results of a study have shown.
A regimen comprising enzalutamide and androgen deprivation therapy (ADT) led to better outcomes compared with a bicalutamide-ADT regimen in an earlier setting of metastatic hormone-sensitive prostate cancer (mHSPC), particularly in Black men, a phase II study suggests.
A novel oral testosterone replacement therapy (TRT*) formulation – testosterone undecanoate (TU) – showed favourable safety and efficacy as long-term treatment for men with low testosterone levels, according to the extension phase results of a study presented at ENDO 2021.
New drug applications approved by US FDA as of 16-31 March 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
In patients with metastatic papillary renal cell carcinoma (PRCC), cabozantinib led to greater progression-free survival (PFS) and overall response rate (ORR) than sunitinib, results of the phase II SWOG 1500 study showed.
Consumption of a newly developed whole tomato‑based food supplement* (WTFS) led to improvements in lower urinary tract symptoms** (LUTS) and quality of life (QoL) in men with benign prostatic hyperplasia (BPH), a phase II Italian study has shown.
Adding apalutamide (APA) to abiraterone acetate and prednisone (AAP) significantly extends radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC) compared with AAP only, according to the final analysis of the ACIS* trial presented at ASCO GU 2021.
In an updated analysis of the phase III POUT* trial presented at ASCO GU 2021, peri-operative chemotherapy continued to improve disease-free survival (DFS) compared with surveillance in patients with upper tract urothelial cancer (UTUC).
Despite high rates of reoperation, most children on sacral neuromodulation (SNM) devices either continue to use these tools or experience symptom improvements enough to permit device removal in the moderate term, according to a new study.
Enfortumab vedotin improved overall survival (OS) compared with chemotherapy in patients with previously treated, locally advanced or metastatic urothelial carcinoma (UC), according to interim results of the phase III EV-301 study.
While early-phase clinical trials may demonstrate substantial levels of overall response rates in patients with relapsed/refractory multiple myeloma (RRMM), high heterogeneity of evidence prevents the accurate assessment of clinical benefit before patient participation, reports a recent meta-analysis.
The COVID-19 vaccine AZD1222 by AstraZeneca and the University of Oxford was 79 percent effective overall in preventing symptomatic infections – higher than observed in previous clinical trials of the vaccine – at the interim analysis of a US phase III trial.
Migraine and headache are common ailments of people living in the modern era. Dr Jon Marshall of The Singapore Headache and Migraine Clinic shares his insights with Pearl Toh on how to manage migraine and headache using non-pharmaceutical strategies, with a focus on the manual medicine approach.